<SEC-DOCUMENT>0001178913-26-002423.txt : 20260506
<SEC-HEADER>0001178913-26-002423.hdr.sgml : 20260506
<ACCEPTANCE-DATETIME>20260506170311
ACCESSION NUMBER:		0001178913-26-002423
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260506
FILED AS OF DATE:		20260506
DATE AS OF CHANGE:		20260506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		26949555

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2635214.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></FONT><B><BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/17.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16<BR>
UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of May 2026</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number 001-38807</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>CHEMOMAB THERAPEUTICS
LTD.</B></FONT><BR>
(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10 Habarzel Street, Building C, 10th
Floor, Tel-Aviv, Israel</B>&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chemomab Therapeutics Ltd. (the &ldquo;Company&rdquo;)
hereby furnishes the results of its annual general shareholders meeting (the &ldquo;Meeting&rdquo;), which was scheduled for April 28,
2026 and adjourned to May 5, 2026, at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat
Gan 5250608, Israel.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Meeting, the Company&rsquo;s shareholders
voted upon and approved, by the requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company&rsquo;s articles
of association (the &ldquo;Articles&rdquo;), the following proposals: (i) the re-election of each of Mr. Neil Cohen and Dr. Claude Nicaise
as Class II directors, (ii) the approval of the compensation policy for office holders and directors, (iii) the approval of an increase
of the Company&rsquo;s authorized share capital and to amend the Company&rsquo;s Articles accordingly, and (iv) the re-appointment of
Somekh Chaikin, a member firm of KPMG international, as the Company&rsquo;s independent registered public accounting firm for the fiscal
year ended December 31, 2026; all in accordance with the Company&rsquo;s proxy statement related to the Meeting, which was attached as
Exhibit 99.1 to the Company&rsquo;s Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on
March 20, 2026.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Form 6-K is incorporated by reference
into the Company&rsquo;s Registration Statements on Form F-3 (File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1534248/000117891323003439/zk2330437.htm">333-275002</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1534248/000117891324002748/zk2431902.htm">333-281750</A>) and Form S-8 (File No. <A HREF="https://www.sec.gov/Archives/edgar/data/1534248/000117891321002984/zk2126574.htm">333-259489</A> and
No. <A HREF="https://www.sec.gov/Archives/edgar/data/1534248/000117891322003108/zk2228346.htm">333-266868</A>).</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 12.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 12.5pt"><FONT STYLE="font-size: 10pt"><B>CHEMOMAB THERAPEUTICS LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 12.5pt; width: 50%">&nbsp;</TD>
    <TD STYLE="line-height: 12.5pt; width: 4%">&nbsp;</TD>
    <TD STYLE="line-height: 12.5pt; width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 12.5pt"><FONT STYLE="font-size: 10pt">Date: May 6, 2026</FONT></TD>
    <TD STYLE="line-height: 12.5pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; white-space: nowrap; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">/s/ Sigal Fattal</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; line-height: 12.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 12.5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">Sigal Fattal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 12.5pt">&nbsp;</TD>
    <TD STYLE="line-height: 12.5pt">&nbsp;</TD>
    <TD STYLE="line-height: 12.5pt"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
